Drugs / personalized vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04943718 | Jul 2021 → Jun 2023 | malignant glioma | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 1 | NCT03568058 | Jul 2018 → Dec 2022 | cancer of unknown primary site | Aaron Miller | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05153304 | Jun 2024 → Jun 2026 | digestive system cancer | University of California, San Diego | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | personalized vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04943718 ↗ |
| Modality | Vaccine | “personalized' vaccine” NCT03568058 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT03568058 ↗ |